biocon biologics - Robuta Search

https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/biocon-biologics-receives-health-canada-approval-for-yesintek-immunology-biosimilar-brand/124757889 Biocon Biologics receives Health Canada approval for Yesintek immunology biosimilar brand, ETPharma Biocon Biologics' immunology biosimilar brand Yesintek secures approval from Health Canada, offering a more affordable treatment option for patients with... biocon biologics health canada https://bioconbiologics.ca/ Biosimilars in Canada | Biocon Biologics Canada Official Site Dec 11, 2025 - Discover how Biocon Biologics supports Canada’s biosimilar ecosystem with high-quality, affordable therapies in oncology, diabetes, immunology, and... in canada biocon biologics biosimilars official site https://www.newswire.ca/news-releases/biocon-biologics-takes-forward-its-mission-to-unlock-universal-access-to-insulins-globally-853015555.html Biocon Biologics Takes Forward its Mission to Unlock Universal Access to Insulins Globally /CNW/ -- Biocon Biologics, a fully integrated 'pure play' global biosimilars organisation, is taking forward its mission of unlocking affordable access to... biocon biologics its mission https://health.economictimes.indiatimes.com/news/pharma/indias-biocon-biologics-launches-biosimilar-for-abbvies-humira-in-us/101472073 India's Biocon Biologics launches biosimilar for AbbVie's Humira in US, ETHealthworld The popular rheumatoid arthritis medication Humira by AbbVie has a biosimilar counterpart that India's Biocon Biologics announced on Monday has been made... biocon biologics https://adisinsight.springer.com/drugs/800087070?error=cookies_not_supported&code=f45f59f7-5e5a-44fc-b91f-2ac8781d3b96 Nivolumab biosimilar - Biocon Biologics - AdisInsight A biosimilar candidate of nivolumab [see Adis Insight drug profile [800022442]], designated as Bmab1700, a monoclonal antibody targeting programmed death-1 biocon biologics nivolumab biosimilar adisinsight https://health.economictimes.indiatimes.com/news/pharma/supply-chain-logistics/biocon-biologics-completes-integration-of-acquired-biosimilars-business-in-70-countries-in-emerging-markets/101520104 Biocon Biologics completes integration of acquired biosimilars business in 70+ countries in... Following the deal closure in November 2022, this marks the first wave of countries where Viatris' operations have fully transitioned to Biocon Biologics. A... biocon biologics completes integration https://www.prnewswire.com/news/biocon-biologics-ltd./ Biocon Biologics Ltd. News and Press Releases | PR Newswire news and press releases biocon biologics ltd newswire https://health.economictimes.indiatimes.com/news/pharma/biocon-mylans-diabetic-drug-receives-positive-opinion-from-european-medicines-agency/79716671 Biocon Biologics: Biocon, Mylan's diabetic drug receives positive opinion from European Medicines... Biocon Biologics: Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is... biocon biologics https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/biocon-biologics-gets-u-s-fda-approval-for-biosimilar-aflibercept-yesafili-enters-us-ophthalmology-market/110294676 Biocon Biologics gets U.S. FDA approval for biosimilar aflibercept Yesafili, enters US... Biocon Biologics: After the approval, the company entered the ophthalmology therapeutic area in the United States. Earlier the company also received approvals... https://pharma.economictimes.indiatimes.com/news/pharma-industry/negative-market-reaction-compelled-to-pursue-biologics-unit-integration-kiran-mazumdar-shaw/125832640 Biocon to Integrate Biologics Unit After Market Setback: Kiran Mazumdar-Shaw, ETPharma Biocon Limited shelves plans for a separate IPO of Biocon Biologics, opting for integration to unlock value amid negative market reactions post-Viatris... after market https://markets.businessinsider.com/bonds/biocon_biologics_global_plcdl-notes_202424-29_regs-bond-2029-usg11185aa61?miRedirects=1 BIOCON BIOLOGICS GLOBAL PLCDL-NOTES 2024(24/29) REG.S Bond | Markets Insider BIOCON BIOLOGICS GLOBAL PLCDL-NOTES 2024(24/29) REG.S (USG11185AA61) - All master data, key figures and real-time diagram. https://legal.economictimes.indiatimes.com/news/regulators/cci-gives-nod-to-edelweiss-biocon-biologics-deal/100110540 CCI Biocon: CCI gives nod to Edelweiss-Biocon Biologics deal, ETLegalWorld CCI Biocon: Fair-trade regulator CCI on Tuesday said it has cleared Edelweiss Alternative Asset Advisors and ESOF III Investment Fund's subscription to certain... cci biocon gives nod edelweiss https://www.business-standard.com/amp/companies/news/biocon-biologics-gets-us-fda-nod-for-jobevne-expands-oncology-portfolio-125041000318_1.html Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio | Company News - Business... Jobevne works by blocking a protein called VEGF, which helps tumours grow new blood vessels https://www.business-standard.com/companies/interviews/will-launch-3-biosimilars-globally-in-2-3-years-biocon-biologics-ceo-124110501250_1.html Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics CEO & MD | Interviews - Business... https://health.economictimes.indiatimes.com/news/finance/biocon-biologics-gets-rs-1125-cr-capital-infusion-from-goldman-sachs/79109396 Biocon Biologics gets Rs 1,125 cr capital infusion from Goldman Sachs, ETHealthworld New Delhi, Nov 7 () Biocon on Saturday said its subsidiary Biocon Biologics has approved a Rs 1,125 crore investment from Goldman Sachs. https://www.business-standard.com/companies/people/biocon-biologics-appoints-kedar-upadhye-as-new-chief-financial-officer-123101900691_1.html Biocon Biologics appoints Kedar Upadhye as new chief financial officer | People - Business Standard Current CFO, MB Chinappa will take on a strategic finance role at Biocon Group chief financial officer https://pharma.economictimes.indiatimes.com/news/regulatory-update/biocon-biologics-drug-substance-facility-receives-5-fda-observations-what-it-means/123755577 Biocon Biologics Drug Substance Facility Receives 5 FDA Observations: What It Means, ETPharma Biocon Biologics faces five procedural observations from the FDA during a recent inspection of its Bengaluru facility, raising questions about compliance and... https://economictimes.indiatimes.com/industry/healthcare/biotech/biocon-biologics-says-clinical-study-for-drug-itolizumab-initiated-in-india-after-approval-from-dcgi/articleshow/88456736.cms biocon: Biocon Biologics says clinical study for drug Itolizumab initiated in India after approval... Biocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical... https://pharma.economictimes.indiatimes.com/news/regulatory-update/fda-classifies-biocons-insulin-plant-in-malaysia-as-voluntary-action-indicated-vai/117170940 Biocon Biologics: FDA Classifies Biocon's Insulin Plant in Malaysia as Voluntary Action Indicated... Biocon Biologics: The cGMP inspection was conducted by the FDA in September 2024 at Biocon's Johor Bahru facility, which houses multiple biologics...